Social Media Giant Spikes Again

By George Banko

April 18, 2022

Good morning Wake-Up Watch listers! While you’re sipping that iced matcha chai latte you’ll see bond yields are on the rise as investors are braced for a big week of earnings. Companies reporting this week include Netflix (Nasdaq: NFLX) and Tesla (Nasdaq: TSLA). Plus, Twitter (NYSE: TWTR) remains in the forefront as the company battles Elon Musk for ownership.

If you want to see how we use earnings reports to make massive gains in the market, check out The War Room. Right now we’re guaranteeing 322 winning trades in 2022 for all members. Click here to get in on those trades.

Here’s a look at the top-moving stocks this morning.

Twitter, Inc. (NYSE: TWTR)

Twitter is up 3.90% premarket as the hype continues to build around Tesla CEO Elon Musk’s offer to buy the company. Last week Musk launched a $43.4 billion hostile takeover bid. This came not long after he revealed a 9% stake in the company. Twitter has struggled as of late. In 2021 they lost $492 million and more losses are expected in the first three months of 2022. But with Musk still looking to buy, Twitter is a stock to keep an eye on.

Carvana Co. (NYSE: CVNA)

Carvana is up 2.99% premarket after the used car platform continues to post strong numbers. The total rental units sold by the firm during the period stood at 113,016, an increase of 57% year-over-year. The gross profit during the quarter was $516 million, an increase of 111% compared to a year ago. Carvana is looking like a solid stock right now.

Keurig Dr. Pepper (Nasdaq: KDP)

Keurig Dr. Pepper is up 2.98% premarket as the coffee company is one of the fastest growing coffee stocks in terms of quarterly year-over-year percentage revenue growth. The company’s revenue has grown 8.7% year-over-year and their earnings per share growth stands at 96.7%. Keurig is looking strong right now.

Nektar Therapeutics (Nasdaq: NKTR)

Nektar Therapeutics is down 7.63% premarket after the company stopped all trials of its key cancer drug following its failure in multiple studies. Nektra and Bristol Myers were testing the combination therapy through an agreement signed in 2020, and last month discontinued two late-stage studies in melanoma patients after one of the trials failed to meet its main goals. Nektar is a stock to be cautious of going forward.